Surfactant replacement therapy in neonates less than 32 weeks gestation: Effect on neonatal intensive care resource utilization
- 1 December 1993
- journal article
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 29 (6), 434-437
- https://doi.org/10.1111/j.1440-1754.1993.tb03015.x
Abstract
The effect of synthetic surfactant (Exosurf) replacement on complications from hyaline membrane disease (HMD) in infants <32 weeks gestation and their resource utilization within a neonatal intensive care unit was studied in 1991‐92. A control group was selected from infants admitted to the same unit during the preceding 3 years when Exosurf was not available. The infants were controlled for gestation, weight and severity of HMD. Infants given Exosurf had a significant reduction in the incidence of pulmonary interstitial emphysema (PIE), and a marginal decrease in the incidence of pneumothorax. They required fewer days on the ventilator and consumed less of the scarce financial resources. There was no difference in the mortality rate among the two groups. The changes seen were more evident among those infants between 30 and 31 weeks gestation, compared to those <28 weeks.Keywords
This publication has 11 references indexed in Scilit:
- Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 gramsThe Journal of Pediatrics, 1992
- Effects of surfactant therapy on outcome of infants with birth weights of 600 to 750 gramsThe Journal of Pediatrics, 1991
- Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactantJournal of Paediatrics and Child Health, 1991
- Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: A multicenter controlled trialThe Journal of Pediatrics, 1991
- A Multicenter Randomized, Placebo-Controlled Trial of Surfactant Therapy for Respiratory Distress SyndromeNew England Journal of Medicine, 1989
- Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Ten Centre Study Group.BMJ, 1987
- DOUBLE-BLIND CONTROLLED TRIAL OF SINGLE-DOSE TREATMENT WITH BOVINE SURFACTANT IN SEVERE HYALINE MEMBRANE DISEASEThe Lancet, 1987
- Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trialThe Journal of Pediatrics, 1985
- Surfactant for Hyaline Membrane DiseasePediatrics, 1980
- Hyaline membrane disease: A discussionThe Journal of Pediatrics, 1972